

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 April 2023 (27.04.2023)



(10) International Publication Number
WO 2023/067021 A1

(51) International Patent Classification:

C07D 417/14 (2006.01) C07D 333/36 (2006.01)
C07D 417/12 (2006.01)

(21) International Application Number:

PCT/EP2022/079131

(22) International Filing Date:

19 October 2022 (19.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21203530.7 19 October 2021 (19.10.2021) EP

(71) Applicant: **IOMX THERAPEUTICS AG** [DE/DE];
Fraunhoferstrasse 13, 82152 Martinsried (DE).

(72) Inventors: **MARSEGLIA, Giuseppe**; c/o Aptuit (Verona)
Srl an Evotec Company, Via Alessandro Fleming, 4, 37135
Verona (IT). **CARUANA, Lorenzo**; c/o Aptuit (Verona)
Srl an Evotec Company, Via Alessandro Fleming, 4, 37135
Verona (IT). **CANELLI, Tommaso**; c/o Aptuit (Verona)
Srl an Evotec Company, Via Alessandro Fleming, 4, 37135
Verona (IT). **ZHAO, Xianglin**; c/o Bellen Chemistry Co
Ltd, Bellen Shanghai Process R&D Center, Bldg 2-101, 999
Jiangyue Rd, Minhang, Shanghai (CN). **WANG, Wenke**; c/
o Bellen Chemistry Co Ltd, Bellen Shanghai Process R&D
Center, Bldg 2-101, 999 Jiangyue Rd, Minhang, Shang-
hai (CN). **ZHAO, Ziqiang**; c/o Bellen Chemistry Co Ltd,
Bellen Shanghai Process R&D Center, Bldg 2-101, 999
Jiangyue Rd, Minhang, Shanghai (CN).

(74) Agent: **KUTTENKEULER, David** et al.; SKM-IP Part-
GmbH, Oberanger 45, 80331 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF

(57) Abstract: The present invention relates to a new scheme and process for the preparation of one specific SIK3 inhibiting compound known as (and described herein as) "E9". Compound E9 has previously been described by the present applicant to show surprisingly superior drug-like properties, such as in respect of target-potency/specificity and ADMET/PK properties, compared to other prior art SIK3 inhibiting compound. The present invention also relates to novel intermediates used in such process of preparing compound E9, as well as to a new methodology used within the process of producing a characteristic key thiophene-based amino intermediate that is used to produce compound E9, and other related aspects as disclosed herein.



WO 2023/067021 A1